Commentary/Review

Kumar P, Bird C, Holland D, Joshi SB, Volkin DB “Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication” Hum Vaccin Immunother Vol 18, No.7 Online Publication (2022)

Blenke, EO, Ornskov E, Schoneich C, Nilsson GA, Volkin DB, Mastrobattista E, Almarsson O, Crommelin DJA. "The storage and in-use stability of mRNA Vaccines and Therapeutics: Not a cold case" J. Pharm Sci.112(2):386-403 (2023)

Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. “Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis?” J. Pharm Sci 111(4):861-867 (2021)

Crommelin DJA, Volkin DB, Hoogendoorn KH, Lubiniecki AS, Jiskoot W. “The science is there: key considerations for stabilizing viral vector-based Covid-19 vaccines” J. Pharm Sci. 110(2):627-34 (2020)

Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. “Addressing the cold reality of mRNA vaccine stability” J. Pharm Sci. 110(3):997-1001 (2020)